Valuation: CSL Limited

Market Cap 42.48B 37.33B 34.84B 31.98B 59.86B 4,069B 61.33B 413B 162B 2,014B 159B 156B 6,961B P/E 2026 *
-47.1x
P/E 2027 * 29.5x
Enterprise Value 51.21B 45B 42B 38.55B 72.16B 4,905B 73.93B 498B 195B 2,427B 192B 188B 8,391B EV / Sales 2026 *
3.33x
EV / Sales 2027 * 3.24x
Free-Float
99.3%
Yield 2026 *
3.21%
Yield 2027 * 3.29%
1 day+6.64%
1 week+8.08%
Current month+12.06%
1 month+11.73%
3 months+1.08%
6 months-29.37%
Current year-21.94%
1 week 19.91
Extreme 19.91
22.52
1 month 19.71
Extreme 19.71
22.54
Current year 16.01
Extreme 16.01
33.53
1 year 16.01
Extreme 16.01
44.77
3 years 16.01
Extreme 16.01
54.5
5 years 16.01
Extreme 16.01
58.62
10 years 16.01
Extreme 16.01
58.99
Manager TitleAgeSince
Chief Executive Officer 63 11/02/2026
Director of Finance/CFO 52 07/10/2025
Chief Operating Officer - 01/05/2025
Director TitleAgeSince
Director/Board Member 72 17/10/2018
Director/Board Member 70 02/02/2011
Director/Board Member 71 09/12/2019
Change 5-day change 1-year change 3-year change Capi.($)
+6.83%+8.08% - - 39.94B
-0.03%+6.90%+24.72%-6.17% 70.73B
+0.28%+3.12%+35.58%+211.60% 54.27B
-4.52%+47.90%+47.90%+47.90% 49.28B
+0.92%+5.65%+63.35%-22.68% 30.36B
-1.63%+11.20%+66.41%+102.07% 25.96B
-1.65%-4.49%+69.81%-52.86% 22.14B
-0.22%-2.66%-4.47%+145.08% 19.96B
-0.91%+2.98%+83.77%+143.13% 16.77B
+1.37%+2.16%+67.45%+129.71% 16.72B
Average +0.06%+2.21%+50.50%+77.53% 34.02B
Weighted average by Cap. +0.05%+2.93%+44.67%+70.75%

Financials

2026 *2027 *
Net sales 15.37B 13.51B 12.61B 11.57B 21.66B 1,472B 22.2B 150B 58.47B 729B 57.72B 56.46B 2,519B 15.58B 13.69B 12.78B 11.72B 21.95B 1,492B 22.49B 151B 59.25B 738B 58.48B 57.21B 2,552B
Net income -974M -856M -799M -733M -1.37B -93.31B -1.41B -9.47B -3.71B -46.17B -3.66B -3.58B -160B 1.19B 1.04B 974M 894M 1.67B 114B 1.71B 11.54B 4.51B 56.26B 4.46B 4.36B 194B
Net Debt 8.73B 7.67B 7.16B 6.57B 12.3B 836B 12.6B 84.88B 33.19B 414B 32.76B 32.05B 1,430B 7.99B 7.02B 6.56B 6.02B 11.26B 766B 11.54B 77.74B 30.4B 379B 30.01B 29.36B 1,310B
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,904
Date Price Change Volume
30/07/26 USD 22.52 +6.83% 206,159
28/07/26 USD 21.08 +3.64% 260,716
27/07/26 USD 20.34 +1.70% 316,371
24/07/26 USD 20.00 -0.79% 219,163
23/07/26 USD 20.16 -3.08% 223,857
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
89.36USD
Average target price
96.97USD
Spread / Average Target
+8.52%

Quarterly revenue - Rate of surprise